Insulet reported $2.04B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Abbott USD 23.5B 1.02B Sep/2026
Align Technology USD 2.73B 63.03M Sep/2026
AtriCure USD 363.39M 17.86M Sep/2026
Baxter International USD 6.83B 163M Sep/2026
Becton, Dickinson and Co. USD 8.32B 178M Sep/2026
Boston Scientific USD 8.16B 192M Sep/2026
Cardinal Health USD 40.99B 2.24B Sep/2026
Cooper Companies USD 2.28B 18.3M Jun/2026
Dexcom USD 3.92B 170.6M Sep/2026
Edwards Lifesciences USD 7.25B 428.6M Sep/2026
Eli Lilly USD 65.26B 591M Sep/2026
Globus Medical USD 2.18B 33.55M Sep/2026
ICU Medical USD 1.22B 8.96M Sep/2026
Inogen USD 203.72M 594K Sep/2025
Insulet USD 2.04B 192.4M Sep/2026
Integra LifeSciences USD 1.19B 1.54M Sep/2026
J&J USD 56.35B 3.42B Sep/2026
Medtronic USD 24.39B 397M Jun/2026
Merit Medical Systems USD 1.2B 86.58M Sep/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Solventum Corp USD 3.69B 49M Sep/2026
Stryker USD 14.18B 235M Sep/2026
Tandem Diabetes Care USD 820.72M 16.08M Sep/2026
Teleflex USD 1.84B 31.2M Sep/2026
West Pharmaceutical Services USD 1.82B 9M Sep/2026
Zimmer Biomet Holdings USD 5.13B 32.3M Sep/2026